Hemophagocytosis-mediated keratinization in oral carcinoma in situ and squamous cell carcinoma: a possible histopathogenesis of keratin pearls. 2013

Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
Division of Oral Pathology, Department of Tissue Regeneration and Reconstruction, Niigata University Graduate School of Medical and Dental Sciences, Chuo-Ku, Niigata, Japan.

Although the histopathogenetic process of keratin pearls is still poorly understood, acceleration of keratinization in squamous cell carcinoma (SCC) cells may represent one possible therapeutic avenue. Based on our histopathological observations, we have hypothesized that SCC cells are keratinized by phagocytosis of extravasated erythrocytes. To confirm this hypothesis, we firstly examined immature keratin pearls in oral carcinoma in situ (CIS) and mature ones in SCC by immunohistochemistry. Concentric dyskeratotic cells in CIS keratin pearls became positive for keratin (K) 10, K17, heme oxygenase-1 (HO-1), or protease activated receptor-2 (PAR-2), a candidate regulator for hemophagocytosis. When ZK-1 cells, an SCC cell system, were incubated with human peripheral blood erythrocytes, or with crude and purified hemoglobins (Hbs), their erythro-hemophagocytotic activities were confirmed by immunofluorescence. Immunofluorescence signals for K10, K17, and HO-1 were enhanced due to hemophagocytosis in time-dependent manners. mRNA expression levels for the three molecules were most enhanced by purified Hb, followed by crude Hb and erythrocytes. K17/K10 mRNA expression levels were more elevated when PAR-2 was activated in ZK-1 cells. The results indicated that immature and mature keratin pearls in CIS and SCC were generated by oxidative stresses derived from erythro-hemophagocytosis, which might mediate HO-1 expression and be regulated by PAR-2. Thus, hemorrhage from the rupture of blood vessels can be one of the triggers for keratin pearl formation in oral CIS and SCC.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D002278 Carcinoma in Situ A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane. Carcinoma, Intraepithelial,Carcinoma, Preinvasive,Intraepithelial Neoplasms,Neoplasms, Intraepithelial,Intraepithelial Carcinoma,Intraepithelial Neoplasm,Neoplasm, Intraepithelial,Preinvasive Carcinoma
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006454 Hemoglobins The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements. Eryhem,Ferrous Hemoglobin,Hemoglobin,Hemoglobin, Ferrous
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D044464 Receptor, PAR-2 A G-protein-coupled, proteinase-activated receptor that is expressed in a variety of tissues including ENDOTHELIUM; LEUKOCYTES; and the GASTROINTESTINAL TRACT. The receptor is activated by TRYPSIN, which cleaves off the N-terminal peptide from the receptor. The new N-terminal peptide is a cryptic ligand for the receptor. The uncleaved receptor can also be activated by the N-terminal peptide present on the activated THROMBIN RECEPTOR and by small synthetic peptides that contain the unmasked N-terminal sequence. PAR-2 Receptor,Proteinase Activated Receptor 2,PAR2 Receptor,Protease-Activated Receptor 2,Receptor, Trypsin,Trypsin Receptor,Trypsin Receptors,PAR 2 Receptor,Protease Activated Receptor 2,Receptor 2, Protease-Activated,Receptor, PAR 2,Receptor, PAR2,Receptors, Trypsin

Related Publications

Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
October 2020, Oral oncology,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
March 2011, Histopathology,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
January 1998, Oncology research,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
August 2021, Gastrointestinal endoscopy,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
January 2022, American journal of translational research,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
August 2015, Tissue & cell,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
June 1984, Gan,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
February 2018, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
December 2014, BMC cancer,
Kamal Al-Eryani, and Jun Cheng, and Tatsuya Abé, and Manabu Yamazaki, and Satoshi Maruyama, and Masayuki Tsuneki, and Ahmed Essa, and Hamzah Babkair, and Takashi Saku
January 2017, Current problems in cancer,
Copied contents to your clipboard!